Abstract
Purpose
Treatment of ulcerative colitis with drugs during pregnancy potentially may harm the mother and the unborn child. Granulocytapheresis depletes elevated/activated myeloid lineage leucocytes as sources of inflammatory cytokines. We were interested in the safety and efficacy of granulocytapheresis in patients who had ulcerative colitis flare up during pregnancy.
Methods
Three pregnant cases with active ulcerative colitis received Adacolumn granulocytapheresis, up to 10 sessions within 3–6 weeks. Case 1: a 33-year-old woman with left-sided colitis and bloody diarrhoea 7–9 times/day showed loss of mucosal vascular patterns, and contact bleeding from the rectum to the sigmoid colon. Case 2: a 36-year-old woman with pancolitis and bloody diarrhoea 6–8 times/day had loss of mucosal vascular patterns and pus from the rectum to the sigmoid colon. Case 3: a 36-year-old woman with pancolitis and diarrhoea 4–5 times/day (first episode) had erosions and pus in the mucosa from the rectum to the transverse colon.
Results
Colitis flare was in weeks 5, 13 and 22 of pregnancy in cases 1, 2, 3, respectively. The corresponding granulocytapheresis sessions were 5, 7, and 10, reflecting an increasing trend with the pregnancy week. Patients 1 and 2 achieved complete remission, patient 3 achieved clinical remission.
Conclusion
In these three cases with active ulcerative colitis during pregnancy, granulocytapheresis as a non-pharmacologic treatment was effective and safe. In case 3 that did not respond well to the initial granulocytapheresis sessions, a moderate dose of prednisolone enhanced the efficacy of granulocytapheresis and tapering of prednisolone shortly after administration was not associated with relapse.
Similar content being viewed by others
References
Allison MC, Dhillon AP, Lewis WG (eds) (1998) Inflammatory bowel disease. Londonm, Mosby, pp 15–95
Vermeire S, Carbonnel F, Coulie PG et al (2012) Management of inflammatory bowel disease in pregnancy. J Crohns Colitis 6:811–823
Mahadevan U (2006) Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 55:1198–1206
Nørgård BM (2011) Birth outcome in women with ulcerative colitis and Crohn’s disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Dan Med Bull 58:B4360
Alstead E, Nelson-Piercy C (2003) Inflammatory bowel disease in pregnancy. Gut 52:159–161
Cornish J, Tan E, Teare J et al (2007) A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56:830–837
Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA (2007) Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 133:1106–1112
Dominitz JA, Young JC, Boyko EJ (2002) Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol 97:641–648
Korelitz BI (1998) Inflammatory bowel disease and pregnancy. Gastroenterol Clin North Am 27:213–224
Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW (1981) Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80:72–76
Gisbert JP (2010) Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 16:881–895
Brown SL, Greene MH, Gershon SK, Edwards ET, Mraun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum 46:3151–3158
Saniabadi AR, Hanai H, Lofberg R et al (2007) Therapeutic leucocytapheresis for inflammatory bowel disease. Transf Aphere Sci 37:191–200
Hanai H, Takeda Y, Saniabadi AR et al (2011) The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 163:50–58
Yamamoto T, Umegae S, Matsumoto K (2012) Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohn’s Colitis 6:750–755
Saniabadi AR, Hanai H, Takeuchi K et al (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory disease associated with leukocytes. Ther Apher Dial 2003(7):48–59
Sakuraba A, Motoya S, Watanabe K et al (2009) An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 104:2990–2995
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y (2004) Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49:565–571
Domenech E, Hinojosa J, Esteve-Comas M (2004) Spanish group for the study of Crohn’s disease and ulcerative colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 20:1347–1352
Caprilli R, D’Ovidio V (2007) Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 39:435–437
Sands BE, Sandborn WJ, Feagan B et al (2008) A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 135:400–409
Lichtiger S, Present DH, Kornbluth A et al (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841–1845
Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629
Oron G, Yogev Y, Shkolnik S et al (2012) Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain. J Matern Fetal Neonatal Med 25:2256–2260
Suzuki Y, Yoshimora N, Saito Y, Saniabadi A (2006) A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 51:2031–2038
Tanaka T, Okanobu H, Yoshimi S et al (2008) Adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 40:731–736
Shimoyama T, Sawada K, Hiwatashi N et al (2001) Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multiple study. J Clin Apher 16:1–9
Tanaka T, Okanobu H, Kuga Y et al (2010) Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol 34:687–695
Kato S, Hosomi E, Amano F et al (2012) The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn’s disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. J Crohns Colitis 6:787–791
Strobl FJ, Voelkerding KV, Smith EP (1999) Management of chronic myeloid leukemia during pregnancy with leukapheresis. J Clin Apher 14:42–44
Ali R, Ozkalemkaş F, Ozkocaman V et al (2004) Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol 34:215–217
Acknowledgments
No external fund was used to carry out this investigation. Further, the authors hereby declare having no conflict of interest in connection with the publication of this manuscript.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takahashi, H., Sugawara, K., Sugimura, M. et al. Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. Arch Gynecol Obstet 288, 341–347 (2013). https://doi.org/10.1007/s00404-013-2748-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-013-2748-5